Design of an Integrative Algorithm for Staging Tuberculosis
NCT03691883
Actinomycetales Infections, Bacterial Infections
Badalona, Barcelona, Spain
View Trial DetailsNCT Number: NCT06893757
The French Tuberculosis Cohort is a prospective, national, multicenter, low-intervention study including subjects aged 18 years and older with tuberculosis disease for which inpatient treatment is initiated. The goal of this observational study is to follow-up and anti-tuberculosis treatment will be provided according to current French recommendations. Participants will provide sociodemographic, clinical, biological, radiological and bacteriological data at various protocol visits at 2 days, 1 and 2 weeks, 2 months, at the end of treatment, 12 and 24 months. Consenting participants will have samples collected at scheduled visits for the establishment of a biobank. This will include blood, urine, breath and hair samples. The positive mycobacterial strains will constitute a specimen bank.
Interested in participating?
Request Info18 year and older
All sexes
Observational
AP-HP Hôpital Saint Louis - Service des Maladies Infectieuses et Tropicales, Paris, France
Main objectif:
To describe the sociodemographic, clinical, radiologic, and bacteriologic characteristics, as well as comorbidities and their impact on treatment outcomes and relapse rate up to 24 months after the start of anti-tuberculosis treatment in people with tuberculosis disease diagnosed in France.
Secondary objectives:
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: through treatment completion; Month 12
Definite cure (microbiological): negative cultures (or direct examination) of respiratory specimens on two occasions during follow-up, in the last month of treatment and on an intermediate specimen, in a participant who has completed treatment and has never met the definition of treatment failure.
Time frame: through treatment completion; Month 12
Probable cure: clinical and radiological improvement of tuberculosis-related symptoms in a participant who has completed treatment and never met the definition of treatment failure.
Time frame: Month 2
Assessed by the conversion (negativation) of cultures specimens on two occasions during follow-up, in the last month of treatment and on an intermediate specimen, in a participant who has completed treatment and has never met the definition of treatment failure.
Time frame: Month 5
Number of Positive culture after 5 months of treatment
Time frame: Month 5
Number of deaths directly related to tuberculosis in the year following diagnosis
Time frame: Month 5
Number of interrupted treatments before the end of the planned duration and not resumed (for a reason other than a rejected tuberculosis diagnosis
Time frame: Month 12
Number of treatment ongoing at 12 months because interrupted for more than two months or modified for resistance, side effects/intolerance, initial failure
Time frame: Month 5
Number of transfers or loss of follow-up
Time frame: Until Month 24
Occurrence and causes of death after tuberculosis diagnosis after inclusion and causes
Time frame: Between end of treatment and Month 24
Recurrence of positive culture of respiratory samples after the end of treatment and after cultures become negative during treatment
Time frame: treatment completion until Month 24
Rate of persistent respiratory symptoms such as coughing, dyspnoea, chest pain and/or wheezing
Time frame: treatment completion until Month 24
Oxygen saturation 88% or lower and PaO2 lower 60 mmHg in ambient air at a distance from an acute episode
Time frame: Baseline, completion or failure treatment (up to 12 months)
and/or impaired lung function as measured by spirometry (FEV1 or FVC <80% of the theoretical value or FEV1/FVC ratio <0.70) iv) and/or radiological sequelae defined as the persistence of pulmonary parenchymal abnormalities (nodules, cavities, reticulations, etc.). The anomalies should not be linked to an obvious cause unrelated to tuberculosis (COPD).
Time frame: Baseline, Month 12, completion or failure treatment
The 3 components of the St Georges's Respiratory Questionnaire (SGRQ): symptoms (frequency and severity), activity (effects on and adjustment of everyday activities), and psychosocial impact. The total score has a maximum of 100 points, with values ranging from 0 to 100.
Time frame: Completion treatment, Month 24
Functional evaluation measured by the 6-minute walk test
Time frame: Completion treatment (up to 12 months), Month 24
Spirometry - FEV1/FVC ratio of greater than 0.70 and both FEV1 and FVC above 80% of the predicted value
Time frame: Baseline, week 2, Month 12, completion or failure of treatment (up to 12 months), Month 24
Pulse oximetry
Time frame: Baseline, Month 2, completion or failure of treatment, Month 24
Imaging (scanner)
Time frame: Baseline, Month 2, completion or failure of treatment (up to 12 months)
Chest X-ray2.Other imaging for extrapulmonary involvement
Time frame: Baseline, During anti-tuberculosis treatment up to Month 12
Psycho-trauma screening (PC-PTSD-5) - 20-item questionnaire, corresponding to the DSM-5 symptom criteria for PTSD. The self-report rating scale is 0-4 for each symptom, reflecting a change from 1-5 in the DSM-IV version.
Time frame: Baseline, Month 2, completion or failure of treatment (up to 12 months)
Anxiety questionnaire (GAD-7) - Score 5-9: Mild Anxiety. Score 10-14: Moderate Anxiety. Score greater than 15: Severe Anxiety. EQ-5D-5L - The UI is calculated from patient scoring of five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). For each dimension, participants are asked to mark between 1: 'no problems' to 5: 'unable to/extreme problems'. Depression (PHQ-9) -Total scores of 5, 10, 15 and 20 represent the thresholds for mild, moderate, moderately severe and severe depression, respectively. Note: Question 9 is a single screening question on suicide risk.
Time frame: Baseline, Day 3, Day 7
Psycho-trauma screening (PC-PTSD-5) - 20-item questionnaire, corresponding to the DSM-5; .symptom criteria for PTSD. The self-report rating scale is 0-4 for each symptom, reflecting a change from 1-5 in the DSM-IV version.Hunger scale (HHS) - rating scale from 0 to 10, where 0 is painful hunger and 10 is painful fullness.
Time frame: Completion of treatment (up to 12 months)
Stigma scale - Responses to each item are measured on a five-point scale (ranging from zero 'strongly disagree' to four 'strongly agree'). Higher scores indicate higher levels of depression stigma.
Time frame: Baseline to Month 24
Alcohol questionnaire (AUDIT-C) - scored on a scale of 0-12 (scores of 0 reflect no alcohol use). In men, a score of 4 or more is considered positive; in women, a score of 3 or more is considered positive. Generally, the higher the AUDIT-C score, the more likely it is that the patient's drinking is affecting his/her health and safety. Tobacco questionnaire (Fagerström) - Test for Nicotine Dependence, the three yes/no items are scored 0 (no) and 1 (yes). The three multiple-choice items are scored from 0 to 3. The items are summed to yield a total score of 0-10.
Time frame: Week 2, Month 2, completion of treatment
Psychoactive substances questionnaire (CAGE-AID) - Item responses on the CAGE are scored 0 or 1, with a higher score an indication of alcohol problems. A total score of 2 or greater is considered clinically significant. A score of 2 to 3 indicates a high index of suspicion and a score of 4 is virtually diagnostic for alcoholism.
Time frame: Baseline, Day 3, Day 7
Questionnaire
Time frame: Baseline, Day 3, Day 7, Month 2, Month 12
PRECAR score
Time frame: Month 2, completion of treatment, Month 12
Questionnaire
Time frame: Baseline, Month 2, completion or failure of treatment (up to 12 months)
Neurocognitive scores - Rankin (MR,) - Measures the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability.
is a 6 point disability scale with possible scores ranging from 0 to 5. A separate category of 6 is usually added for patients who expire.
Contact information is provided by the study sponsor or research team.
ANRS, Emerging Infectious Diseases
Other Gov
Prospective Cohort of People Starting Treatment for Tuberculosis Disease in France - ANRS 464s FrenchTB
Acronym: FrenchTB
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03691883
Actinomycetales Infections, Bacterial Infections
Badalona, Barcelona, Spain
View Trial DetailsNCT03458338
Actinomycetales Infections, Bacterial Infections
Basel, Switzerland
View Trial DetailsNCT00004276
Acquired Immunodeficiency Syndrome, Actinomycetales Infections
View Trial DetailsNCT01212003
Actinomycetales Infections, Bacterial Infections
Bethesda, Maryland, United States
View Trial Details